Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Mar 21, 2023
Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)
Mar 8, 2023
Sanofi Canada Maintains Gender Parity Certification, Achieving Platinum Level
Photos
1
Jan 18, 2023
Health Canada accepts nirsevimab regulatory submission for infant RSV
Oct 26, 2022
Canadians Encouraged to Live "In Range" to Better Manage their Diabetes
Jun 22, 2022
Sanofi to Launch Artificial Intelligence Centre of Excellence in Toronto
Jun 16, 2022
Sanofi Canada awards second annual Sanofi Biogenius Canada Grants, supporting access to hands-on STEM learning for Canadian students
Jun 15, 2022
Sanofi Canada announces winners of 2022 Sanofi Biogenius Canada Competition
Jun 14, 2022
Sanofi Canada furthers commitment to Canadians living with diabetes through mental health resources provided by MindBeacon
May 10, 2022
Sanofi Biogenius Canada Competition returns to Canada-Wide Science Fair
May 3, 2022
Sanofi achieves the third year of Gold-level Gender Parity Certification
Mar 28, 2022
Dupixent® (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
Mar 25, 2022
Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
Jan 25, 2022
Sanofi Canada named one of Forbes Canada's Best Employers for 2022
Dec 9, 2021
Sanofi Canada supports Canada's Walk of Fame in its induction of Frederick Banting, Charles Best, James Collip and John Macleod in the 100th anniversary year of their discovery of insulin
Nov 15, 2021
Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency)
Nov 10, 2021
Canadians living with diabetes want increased mental health resources, are interested in taking a 360-approach towards holistic car
Oct 29, 2021
Libtayo® (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients
Oct 29, 2021
Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells with no EGFR, ALK or ROS1 aberrations
Oct 13, 2021
New SARCLISA® (isatuximab for injection) Combination Now Approved by Health Canada for Adults with Relapsed and/or Refractory Multiple Myeloma
Jul 22, 2021
DUPIXENT® (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma
Jul 2, 2021
Sanofi Canada continues to invest in modern diabetes research to improve outcomes for people living with diabetes
Jun 28, 2021
New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin
Jun 17, 2021
DUPIXENT® (dupilumab injection) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases
Jun 10, 2021
Sanofi Canada awards first annual Biogenius Grants, strengthening equity in STEM learning for Canadian students
Jun 1, 2021
Quebec extends public reimbursement of DUPIXENT® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis to include adolescents
Show
5
10
25
50
100
per page
«
1
2
3
4
»